Search
SOLACI Congress
HomeFilePharmacology

Pharmacology

View Category

Other

AHA 2018 | Canakinumab Reduces Hospitalization for Cardiac Failure in Respondents

The benefit was dose-dependent reduction, regardless the presence of absence of baseline cardiac failure. Patients with prior...
solaci -
Learn More
Antithrombotic Anticoagulants

Safety of Combining New Anticoagulant Agents and Dual Antiplatelet Therapy

Atrial fibrillation is the most common arrhythmia and its combination with a history of acute myocardial infarction...
solaci -
Learn More
Antithrombotic Anticoagulants

New Anticoagulant Agents in Atrial Fibrillation in Latin American Patients, Specifically

There is limited information on the use of antithrombotic therapies and their outcomes in Latin American patients...
solaci -
Learn More
Antithrombotic Anticoagulants

Galileo: Rivaroxaban After TAVR Stopped Due to Early Event Rates

Patients undergoing transcatheter aortic valve replacement (TAVR) randomized to rivaroxaban in the GALILEO trial experienced higher risk...
solaci -
Learn More
Pharmacology

Is Stage 1 Hypertension as Defined in ACC/AHA Guidelines Associated with Any Events?

New information has been published fast, and what we thought we knew about hypertension has also changed...
solaci -
Learn More
Coronary disease

The 10 most read articles of September

1- High-Sensitivity Troponins Turned All Events into Infarctions; the 4th Universal Definition Clarifies Things Myocardial infarction or myocardial...
solaci -
Learn More
Antithrombotic Anticoagulants

TCT 2018 | OAC-ALONE: Anticoagulation Alone 1 Year After Stenting in Patients with Atrial Fibrillation

Up to now, there had been no randomized controlled trial assessing oral anticoagulation alone vs. oral anticoagulation...
solaci -
Learn More
Pharmacology

What to Do with Blood Pressure Levels Between 130/80 and 139/89 mmHg

The decision to be made with a treatment-free patient with systolic blood pressure over 160 mmHg or diastolic...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Perforation Management in Bifurcations: Bench Testing of Bailout with Covered Stents

Dr. Omar Tupayachi - 0
Coronary perforations during PCI are one of the most dreaded complications in interventional cardiology, especially in bifurcations. Though rate, this critical situation requires an...

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Dr. Omar Tupayachi - 0
Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Dr. Omar Tupayachi - 0
Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy